Anzeige
Mehr »
Samstag, 09.08.2025 - Börsentäglich über 12.000 News
Das Kupferangebot bricht ein - und dieser neue Fund kommt genau zur richtigen Zeit
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41081 | ISIN: CA23809L2075 | Ticker-Symbol: D4G0
Tradegate
06.08.25 | 12:47
0,059 Euro
+14,56 % +0,008
Branche
Hardware
Aktienmarkt
Sonstige
1-Jahres-Chart
DATAMETREX AI LIMITED Chart 1 Jahr
5-Tage-Chart
DATAMETREX AI LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0430,06108.08.
0,0480,05608.08.
ACCESS Newswire
602 Leser
Artikel bewerten:
(2)

DataMetrex AI Ltd.: Datametrex Acquires Arbutus Health And Wellness Inc.

TORONTO, ON / ACCESS Newswire / June 6, 2025 / Datametrex AI Limited (the "Company" or "Datametrex') (TSXV:DM)(FSE:D4G)(OTC PINK:DTMXF) is pleased to announce that further to its news release dated April 1, 2025, it has completed the acquisition of all of the issued and outstanding share capital of Arbutus Health and Wellness Inc. ("Arbutus Health"), a multidisciplinary medical clinic in Vancouver, Canada.

Arbutus Health provides walk-in services, family medicine, skin laser treatments, and other specialty healthcare services in a single location. Once operational, the clinic will be staffed by licensed healthcare professionals and will provide patients with access to multiple medical services without requiring multiple referrals.

The acquisition of Arbutus was completed by way of a share exchange agreement dated June 5, 2025 between the Company, Arbutus and the shareholders of Arbutus pursuant to which Datametrex acquires 100% of the issued and outstanding shares of Arbutus Health, an arm's length party, in exchange for an aggregate of 11,000,000 common shares of Datametrex at a deemed value of $0.10 per share (the "Payment Shares"). As a result of the transaction, Arbutus is now a wholly-owned subsidiary of Datametrex.

Upon completion of the Transaction, Paul Haber, the CEO of the Company, commented, "We are excited to finalize this agreement and are eager to integrate the Arbutus Health team into Datametrex. This acquisition marks a key milestone in broadening our product portfolio and enhancing our presence in the healthcare sector."

Issuance of the Payment Shares is subject to the receipt of regulatory approvals including, without limitation, the final approval of the TSX Venture Exchange ("TSXV") and other conditions.

Datametrex has not assumed any debt of Arbutus and the proposed acquisition will not constitute a fundamental change or result in a change of business for the Company, nor is it expected to result in a change of control of the Company within the meaning of applicable securities laws and defined in the polices of the TSXV.

About Arbutus Health

Arbutus Health is a multidisciplinary medical clinic designed to address wait times and fragmented care in Canada's health system. Walk-in services, family doctors, skin laser treatments, and other specialties are integrated under one roof to provide timely and comprehensive care without requiring multiple referrals. Staffed by licensed healthcare professionals, patient satisfaction will be enhanced through innovative, efficient, and high-quality healthcare solutions.

About Datametrex

Datametrex is an innovative leader in Technology Solutions, Artificial Intelligence, Healthcare, and Mobile Gaming. The Company excels in delivering tools and solutions that enhance operational efficiencies and business outcomes. With a commitment to innovation, Datametrex is dedicated to supporting enterprises by setting a new standard for business protocols through cutting-edge technology.

For more on Datametrex, please visit our Company website.

For Additional Information

Paul Haber, C.P.A., C.A., C.Dir
CEO & Chairman
info@datametrex.com
(416) 318-6501

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains "forward-looking statements," which involve risks, uncertainties, and factors that could cause actual results to differ materially from those anticipated. These statements are not historical facts and are generally identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," and similar expressions. Such statements include expectations related to healthcare business and other Company plans.

While Datametrex believes the forward-looking information is reasonable as of the date of this release, these statements involve assumptions, risks, and uncertainties that could cause actual outcomes to differ. Key factors include general economic conditions, legislative and regulatory developments, access to capital, industry competition, and the Company's ability to execute its strategies. The Company does not undertake to update these statements, except as required by law. Readers are advised not to place undue reliance on forward-looking information.

Factors that could cause actual results to differ materially are detailed under "Risk Factors" in Datametrex's management's discussion and analysis and available on the Company's profile at www.sedarplus.ca.

This release does not constitute an offer to sell or a solicitation to buy, nor shall it constitute an offer, solicitation, or sale in any jurisdiction where such would be unlawful prior to registration or qualification under applicable securities laws. We seek Safe Harbor.

SOURCE: Datametrex AI Ltd.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/datametrex-acquires-arbutus-health-and-wellness-inc.-1036191

© 2025 ACCESS Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.